• Filipin III and the SOAT1–Fibrosis Connection

  2026-10-19

  Ding et al. linked PHMG-induced pulmonary fibrosis to SOAT1-associated cholesterol-ester accumulation, impaired lipophagy, and pro-fibrotic alveolar macrophage responses. Filipin III contributed a free-cholesterol readout within this evidence chain, but the fibrosis mechanism was supported by convergent histological, transcriptomic, lipidomic, cellular, and pharmacological findings rather than by Filipin III staining alone.

• AS1842856: A Bounded Foxo1 Inhibitor Overview

  2026-10-19

  APExBIO describes AS1842856 as a selective Foxo1 inhibitor that reduces Foxo1 activity without changing reported Foxo1 abundance. The product page associates it with reduced gluconeogenic gene expression, glucose production, and selected glucose readouts in cellular and mouse models. Because no identity-matched paper, methods, sample sizes, or uncertainty estimates are provided, these claims should be treated as supplier-reported evidence rather than an independently verified literature record.

• MTSEA-biotin: What the Record Supports

  2026-10-18

  The available product entry identifies MTSEA-biotin as SKU C5669 and associates it with APExBIO, but provides no chemical description, mechanism, study citation, assay readout, or outcome data. A defensible overview can therefore establish only catalog-level identity and the limits of interpretation; it cannot substantiate a reactive group, labeling mechanism, measurement performance, or research application.

• H-151, Ferroptosis, and Renal IRI

  2026-10-17

  An in-press study reports that H-151 protected cultured cells and mice from ferroptosis-associated injury through a mechanism that extended beyond STING inhibition. The evidence supports a model in which H-151 acts as a radical-trapping antioxidant while also suppressing STING signaling, but the findings remain preclinical and do not establish clinical efficacy, supplier-specific performance, or that ML-210 itself is protective.

• Demecycline: Identity, Mechanism, and Evidence Limits

  2026-10-16

  The APExBIO product description identifies Demecycline as a C6 demethylated tetracycline derivative and labels it a bacterial protein synthesis inhibitor. That documentation supports a limited identity and mechanism overview, but it does not establish a molecular target, assay readout, comparative activity, respiratory-infection model result, or clinical efficacy.

• Nocodazole and Spiroplasma Cell Entry

  2026-10-16

  Evidence from a Drosophila S2-cell model supports a role for clathrin-mediated endocytosis, macropinocytosis, and intact actin–microtubule networks in intracellular Spiroplasma eriocheiris infection. Nocodazole-sensitive reduction in intracellular bacterial copy number is informative about cytoskeletal dependence, but it does not by itself distinguish impaired entry from altered trafficking, intracellular survival, replication, or host-cell physiology.

• Uric Acid Assay Kit: Scope and Evidence

  2026-10-15

  The APExBIO Uric Acid Colorimetric/Fluorometric Assay Kit is documented as a research-use reagent system for measuring uric acid in serum and urine through absorbance or fluorescence readouts. The available material supports a limited product and measurement overview, but contains no identity-matched study establishing analytical performance, clinical validity, or diagnostic utility.

• Isradipine (Dynacirc): Mechanism and Evidence Scope

  2026-10-15

  Isradipine (Dynacirc) is identified by APExBIO as a dihydropyridine L-type voltage-gated calcium channel antagonist. The product description connects calcium-channel blockade with vascular smooth muscle relaxation and antihypertensive activity, while presenting neuroprotection in calcium-mediated excitotoxicity as a research rationale rather than a demonstrated outcome. No identity-matched research study, effect estimate, or neuronal assay result is available in the cited material.

• Aprotinin: Mechanism, Scope, and Evidence Boundaries

  2026-10-14

  Aprotinin, also called bovine pancreatic trypsin inhibitor or BPTI, is described by APExBIO as a reversible inhibitor of several serine proteases, including trypsin, plasmin, and kallikrein. The product information provides a biochemical framing and reported IC50 range, alongside claims concerning fibrinolysis, inflammatory markers, and animal-model outcomes. However, no identity-matched research paper, comparator, sample size, or uncertainty estimate is available here, so these claims should be treated as catalog-reported scope rather than independently verified evidence for SKU A2574.

• Esculetin and Post-Stroke Inflammation: Evidence Limits

  2026-10-14

  A mouse study links esculetin’s reported effects after ischemic stroke to reduced CKLF1-associated neutrophil recruitment, but the findings remain preclinical and do not establish clinical efficacy, safety, or applicability to human stroke.

• H-151, Ferroptosis, and What the Evidence Shows

  2026-10-13

  A supplied 2026 study reports that H-151, a STING inhibitor, also suppresses ferroptosis through radical-trapping antioxidant activity. The findings support a mechanistic link between inflammatory signaling and lipid-peroxidation-driven cell death in renal ischemia-reperfusion injury, but they do not establish clinical efficacy or identify ML-210 as equivalent to H-151.

• Arachidonic Acid in Stroke Research Context

  2026-10-13

  The reported rat study supports further investigation of selective hypothermic human serum albumin perfusion as a preclinical approach to cerebral ischemia-reperfusion injury. It does not test Arachidonic Acid, and its findings should not be interpreted as evidence for arachidonate-based stroke treatment. The available evidence remains limited by the animal model, incomplete outcome details in the supplied summary, and uncertain clinical applicability.

• Lovastatin and Floral Meristem Evidence Gaps

  2026-10-12

  The supplied Arabidopsis study establishes KNUCKLES as a regulator of floral meristem termination through auxin distribution, cytokinin activity, and repression of PIN1 and IPT7. It does not test Lovastatin or compare HMG-CoA reductase inhibition with the KNU pathway. Any connection between these systems therefore remains a hypothesis rather than a published finding.

• Indomethacin: What the Evidence Supports

  2026-10-12

  Indomethacin is a nonsteroidal anti-inflammatory drug with reported cyclooxygenase inhibition and additional, context-dependent activities. The supplied renal-injury study concerns CDCA, FXR, KLF11 and JAK2/STAT3—not indomethacin—so its findings should not be used to infer renal, anti-inflammatory or clinical effects for this compound.

• 2-D08 and the Evidence for SUMOylation Research

  2026-10-11

  2-D08 (2’,3’,4’-trihydroxyflavone) is described by APExBIO as an inhibitor of SUMO transfer at the substrate-conjugation step. The supplied evidence supports its use as a mechanistic research tool, not as a validated treatment for cancer, bronchopulmonary dysplasia, or other disease. A 2026 in-press study links ETS1, SENP2, HSPA8, and FUNDC1 to mitophagy in experimental bronchopulmonary dysplasia models, but it did not test 2-D08.

3650 records 1/244 page Next 12345 下5页 Last page